A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB

The novel meningococcal serogroup B vaccine (4CMenB, Bexsero(®)), recently approved in Europe and Australia, may soon be included in routine infant immunization schedules, subject to guidance from national or regional recommending bodies. In the development of 4CMenB and consistent with other newly...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Prymula, Roman, Esposito, Susanna, Zuccotti, Gian Vincenzo, Xie, Fang, Toneatto, Daniela, Kohl, Igor, Dull, Peter M
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186040/
https://ncbi.nlm.nih.gov/pubmed/25424809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.28666
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares